6505--Aprepitant Capsules
ID: 36E79725R0029Type: Presolicitation
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNAC PHARMACEUTICALS (36E797)HINES, IL, 60141, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)
Timeline
    Description

    The Department of Veterans Affairs (VA) is issuing a presolicitation notice for Request for Proposal (RFP) 36E79725R0029 concerning the procurement of Aprepitant Capsules, aimed at ensuring a continuous supply for various federal entities, including the Department of Defense and the Bureau of Prisons. Offerors are required to provide a unique National Drug Code (NDC) number and ensure that their label is the sole representation on the product, with the contract set for one year plus four optional annual extensions. This procurement is critical for serving veterans and other federal health care facilities, with substantial estimated annual requirements for Aprepitant in various dosages. Interested parties should note that the solicitation will be released around March 25, 2025, with a closing date of April 8, 2025, and are encouraged to contact Matthew Poulin at matthew.poulin@va.gov for inquiries.

    Point(s) of Contact
    Matthew PoulinContract Specialist
    (708) 786-5186
    matthew.poulin@va.gov
    Files
    Title
    Posted
    The Department of Veterans Affairs (VA) is issuing a presolicitation notice for Request for Proposal (RFP) 36E79725R0029 concerning the procurement of Aprepitant Capsules. This unrestricted procurement will cater to various federal entities, including the Department of Defense and the Bureau of Prisons, with the goal of ensuring a continuous supply of the medication. The contract will have a duration of one year plus four optional annual extensions. Offerors must provide a unique National Drug Code (NDC) number and ensure their label is the sole representation on the product. The solicitation is set to be released around March 25, 2025, with a closing date of April 8, 2025. It emphasizes the necessity for interested parties to stay updated via the SAM.gov website, as no paper copies will be provided. The estimated annual requirements indicate substantial quantities of Aprepitant in various dosages, highlighting the importance of this procurement in serving veterans and other federal health care facilities. Matthew Poulin serves as the point of contact for inquiries regarding this solicitation, reinforcing communication between the VA and potential offerors for clarification and submission processes.
    Lifecycle
    Title
    Type
    6505--Aprepitant Capsules
    Currently viewing
    Presolicitation
    Similar Opportunities
    6505--Carvedilol Tablets (VA-25-00048048)
    Buyer not available
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Carvedilol Tablets under solicitation number 36E79725R0028, aimed at ensuring a continuous supply for various federal health care entities, including the Department of Defense and the Bureau of Prisons. The contract will be for one year, with the possibility of four additional one-year extensions, requiring offerors to supply drugs labeled with their unique National Drug Code (NDC) without altering existing labels. This procurement is critical for maintaining the availability of essential medications for veterans and affiliated populations, underscoring the VA's commitment to effective health care delivery. Interested bidders should monitor SAM.gov for updates, with the RFP expected to be issued around March 19, 2025, and responses due by April 2, 2025; inquiries can be directed to Contract Specialist Adrienne Albachiara at adrienne.albachiara@va.gov or by phone at 708-202-9027.
    6505--Loperamide Capsules (VA-25-00032225)
    Buyer not available
    The Department of Veterans Affairs (VA) is issuing a presolicitation notice for the procurement of Loperamide HCL 2MG Capsules under Request for Proposal (RFP) 36E79725R0025. This procurement aims to ensure a consistent supply of the medication not only for the VA but also for the Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC), with the intention to award one contract that spans one year with four optional one-year extensions. The estimated requirements include 18,690 bottles of 100 capsules and 47,289 bottles of 500 capsules annually, reflecting the importance of maintaining a steady supply of essential medications for healthcare facilities. Interested parties should note that the solicitation is expected to be electronically issued by April 17, 2025, with responses due by May 1, 2025; inquiries can be directed to Contracting Officer Andrew Cazares at Andrew.Cazares@va.gov or (719) 786-4990.
    6509--Solifenacin Tabletes (VA-25-00037090)
    Buyer not available
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Solifenacin Tablets, designated as RFP 36E79725R0020. This procurement aims to establish a reliable supply of Solifenacin for the VA, Department of Defense (DoD), and other federal health agencies, with the contract expected to last one year and include four optional renewal periods. Solifenacin is a critical medication used in the treatment of overactive bladder, highlighting the VA's commitment to ensuring access to essential pharmaceuticals for veterans and associated healthcare providers. Interested vendors should monitor SAM.gov for the RFP release, anticipated around March 14, 2025, with proposals due by March 28, 2025; for further inquiries, they may contact Contract Specialist Kenneth Lay at Kenneth.Lay@va.gov or by phone at 708-786-4879.
    6505--Fludrocortisone Acetate Tablets (VA-25-00047932)
    Buyer not available
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for Fludrocortisone Acetate 0.1MG Tablets, packaged in bottles of 100 tablets, to ensure a reliable supply for various federal entities, including the Department of Defense (DOD), Bureau of Prisons (BOP), and Indian Health Service (IHS). The procurement aims to award a single contract that covers an initial term of one year, with the option for four additional one-year periods, thereby securing an uninterrupted source of this essential medication. The estimated annual requirement for the tablets is 31,127 bottles, and interested suppliers must provide a unique NDC or UPC number along with the product name as it appears on the label. The solicitation is expected to be published on or around March 28, 2025, with proposals due by April 11, 2025; inquiries can be directed to Youlanda Duggar at Youlanda.Duggar@va.gov or by phone at 708-786-4943.
    6505--Hydroxychloroquine SO4 Tablets
    Buyer not available
    The Department of Veterans Affairs (VA) is issuing a Request for Proposal (RFP) for the procurement of Hydroxychloroquine SO4 Tablets, aimed at ensuring a continuous supply for various federal entities, including the Department of Defense and the Bureau of Prisons. The contract will cover an estimated annual requirement of 163,395 bottles of 100-count and 25,853 bottles of 500-count Hydroxychloroquine tablets, with a contract period of one year and four optional one-year extensions. This procurement is critical for maintaining essential medications within veteran and federal healthcare programs. Interested parties should monitor SAM.gov for updates and direct inquiries to the contracting officer, Chris Carthron, at Christopher.Carthron@va.gov or (708) 786-4980, with submissions due by March 26, 2025.
    6505--760-25-1-050-0237 -Leavenworth CMOP OM PHARMACEUTICALS -(VA-25-00028391)
    Buyer not available
    The Department of Veterans Affairs (VA) is preparing to issue a request for proposal (RFP) for the procurement of fourteen specified pharmaceuticals to be delivered to the Leavenworth Consolidated Mail Outpatient Pharmacy (CMOP) facility in Kansas. This opportunity is exclusively set aside for small businesses under the product service code 6505, which pertains to drugs and biologicals, and requires interested vendors to submit a price schedule, a signed SF1449 cover page, valid state wholesale distributor licenses, and a Buy American Act certificate. The procurement is crucial for ensuring that veterans receive timely access to necessary pharmaceuticals, with the estimated RFP issue date set for March 6, 2025, and a response deadline of March 17, 2025. Interested parties should direct their submissions and inquiries to Contracting Officer Kelley Cunningham at kelley.cunningham@va.gov or by phone at 913-684-0140.
    Dimethyl Fumarate DR Presolicitation
    Buyer not available
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    6505--Insulin (VA-25-00026482)
    Buyer not available
    The Department of Veterans Affairs is soliciting proposals for the procurement of insulin and its derivatives under the solicitation titled "6505--Insulin (VA-25-00026482)." This procurement aims to establish a reliable supply source for pharmaceutical products, specifically focusing on competitive pricing for a base year plus four option years, while ensuring compliance with the Drug Supply Chain Security Act (DSCSA) and good manufacturing practices (cGMP). The contract is critical for maintaining quality healthcare for government participants, and interested offerors must submit their proposals by March 14, 2025, at 2:30 PM Central Standard Time, with all submissions including a 0.5% Cost Recovery Fee. For further inquiries, potential contractors can contact Contract Specialist Billy Fong at Billy.Fong@va.gov.
    6505--Fluticasone Propionate 50 MCG/Spray Soln, Nasal, 16GM
    Buyer not available
    The Department of Veterans Affairs is soliciting bids for the supply of Fluticasone Propionate nasal spray, a pharmaceutical product essential for various government healthcare facilities. Offerors are required to submit pricing for a base year and four option years, including a 0.5% Cost Recovery Fee, while ensuring compliance with federal standards and providing a unique National Drug Code (NDC) for each product. This procurement aims to secure reliable pharmaceutical sources to support healthcare services for veterans and other governmental health programs, adhering to strict FDA guidelines and good manufacturing practices. Interested contractors should contact Contract Specialist Michael J Olszewski at Michael.Olszewski@va.gov for further details on submission procedures and compliance requirements.
    Rabeprazole Sodium Delayed Release Tablets
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.